Is the genomic translational pipeline being disrupted?

The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples of potential disruptors such as laboratory-developed tests, direct-to-co...

Descripción completa

Detalles Bibliográficos
Autor principal: Williams, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Opinion Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466858/
https://www.ncbi.nlm.nih.gov/pubmed/26070310
http://dx.doi.org/10.1186/s40246-015-0032-4
_version_ 1782376295784513536
author Williams, Marc S.
author_facet Williams, Marc S.
author_sort Williams, Marc S.
collection PubMed
description The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples of potential disruptors such as laboratory-developed tests, direct-to-consumer testing, and patient-centered research are presented. Awareness of the disruptive nature of innovative approaches is necessary if these innovations are to be incorporated into current practice.
format Online
Article
Text
id pubmed-4466858
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44668582015-06-16 Is the genomic translational pipeline being disrupted? Williams, Marc S. Hum Genomics Opinion Article The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples of potential disruptors such as laboratory-developed tests, direct-to-consumer testing, and patient-centered research are presented. Awareness of the disruptive nature of innovative approaches is necessary if these innovations are to be incorporated into current practice. BioMed Central 2015-06-14 /pmc/articles/PMC4466858/ /pubmed/26070310 http://dx.doi.org/10.1186/s40246-015-0032-4 Text en © Williams. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Opinion Article
Williams, Marc S.
Is the genomic translational pipeline being disrupted?
title Is the genomic translational pipeline being disrupted?
title_full Is the genomic translational pipeline being disrupted?
title_fullStr Is the genomic translational pipeline being disrupted?
title_full_unstemmed Is the genomic translational pipeline being disrupted?
title_short Is the genomic translational pipeline being disrupted?
title_sort is the genomic translational pipeline being disrupted?
topic Opinion Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466858/
https://www.ncbi.nlm.nih.gov/pubmed/26070310
http://dx.doi.org/10.1186/s40246-015-0032-4
work_keys_str_mv AT williamsmarcs isthegenomictranslationalpipelinebeingdisrupted

Ejemplares similares